(Pro)renin receptor in skeletal muscle is involved in the development of insulin resistance associated with postinfarct heart failure in mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 307, Issue 6, 2014, Pages E503-E514

  Fukushima, Arata ^a   Kinugawa, Shintaro ^a   Takada, Shingo ^a,c   Matsushima, Shouji ^a   Sobirin, Mochamad Ali ^a,b   Ono, Taisuke ^a   Takahashi, Masashige ^a   Suga, Tadashi ^a,c   Homma, Tsuneaki ^a   Masaki, Yoshihiro ^a   Furihata, Takaaki ^a   Kadoguchi, Tomoyasu ^a   Yokota, Takashi ^a   Okita, Koichi ^d   Tsutsui, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DIPONEGORO UNIVERSITY   (Indonesia)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^d HOKUSHO UNIVERSITY   (Japan)

Author keywords

(Pro)renin receptor; Heart failure; Insulin resistance; Oxidative stress; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; GLUCOSE TRANSPORTER 4; HANDLE REGION PEPTIDE; INSULIN; LOSARTAN; NITRITE REDUCTASE [NAD(P)H]; OXYGEN; PEPTIDE DERIVATIVE; PRORENIN; PRORENIN RECEPTOR; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SERINE; SUPEROXIDE; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; ONCOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HORMONE BLOOD LEVEL; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; OXYGEN TISSUE LEVEL; PLASMA RENIN ACTIVITY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SURVIVAL RATE; UPREGULATION; WESTERN BLOTTING; (PRO)RENIN RECEPTOR; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; ELECTROCARDIOGRAPHY; GENETICS; HEART FAILURE; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; METABOLISM; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

(PRO)RENIN RECEPTOR; HEART FAILURE; INSULIN RESISTANCE; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

ANGIOTENSINOGEN; ANIMALS; CELL LINE; ELECTROCARDIOGRAPHY; HEART FAILURE; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOCARDIAL INFARCTION; NADPH OXIDASE; ONCOGENE PROTEIN V-AKT; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHOSPHORYLATION; RECEPTORS, CELL SURFACE; RENIN-ANGIOTENSIN SYSTEM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84907804793     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00449.2013     Document Type: Article

References (48)

1. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan in Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110: 1572-1578, 2004.
2. ALLHAT Authors. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002.
3. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50: 439-465, 2010.
4. Batenburg WW, Danser AJ. Prorenin and the (pro)renin receptor: binding kinetics, signalling and interaction with aliskiren. J Renin-Angiotensin-Aldosterone System 9: 181-184, 2008.
5. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26: 2433-2441, 2003.
6. Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 77: 8C-16C, 1996.
7. Clavreul N, Sansilvestri-Morel P, Magard D, Verbeuren TJ, Rupin A. (Pro)renin promotes fibrosis gene expression in HEK cells through a Nox4-dependent mechanism. Am J Physiol Renal Physiol 300: F1310-F1318, 2011.
8. de Resende MM, Kauser K, Mill JG. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sci 78: 3066-3073, 2006.
9. Djousse L, Benkeser D, Arnold A, Kizer JR, Zieman SJ, Lemaitre RN, Tracy RP, Gottdiener JS, Mozaffarian D, Siscovick DS, Mukamal KJ, Ix JH. Plasma free fatty acids and risk of heart failure: the Cardiovascular Health Study. Circ Heart Fail 6: 964-969, 2013.
10. Doehner W, Gathercole D, Cicoira M, Krack A, Coats AJ, Camici PG, Anker SD. Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. Int J Cardiol 138: 19-24, 2010.
11. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46: 1019-1026, 2005.
12. Dzau VJ. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37: 1047-1052, 2001.
13. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 19: 743-748, 2008.
14. Gassmann M, Grenacher B, Rohde B, Vogel J. Quantifying Western blots: pitfalls of densitometry. Electrophoresis 30: 1845-1855, 2009.
15. Handayaningsih AE, Iguchi G, Fukuoka H, Nishizawa H, Takahashi M, Yamamoto M, Herningtyas EH, Okimura Y, Kaji H, Chihara K, Seino S, Takahashi Y. Reactive oxygen species play an essential role in IGF-I signaling and IGF-I-induced myocyte hypertrophy in C2C12 myocytes. Endocrinology 152: 912-921, 2011.
16. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611-616, 1999.
17. Hirose T, Mori N, Totsune K, Morimoto R, Maejima T, Kawamura T, Metoki H, Asayama K, Kikuya M, Ohkubo T, Kohzuki M, TakahashiK, Imai Y. Gene expression of (pro)renin receptor is upregulated in hearts and kidneys of rats with congestive heart failure. Peptides 30: 2316–2322, 2009.
18. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440: 944-948, 2006.
19. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Invest 114: 1128-1135, 2004.
20. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Nakagawa T, Nishiyama A, Kawachi H, Shimizu F, Inagami T. Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 17: 2495-2503, 2006.
21. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47: 894-900, 2006.
22. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA 294: 334-341, 2005.
23. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87: 392-398, 2000.
24. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh S, Takamoto I, Sasako T, Kumagai K, Kawai T, Hashimoto S, Kobayashi T, Sato M, Tokuyama K, Nishimura S, Tsunoda M, Ide T, Murakami K, Yamazaki T, Ezaki O, Kawamura K, Masuda H, Moroi M, Sugi K, Oike Y, Shimokawa H, Yanagihara N, Tsutsui M, Terauchi Y, Tobe K, Nagai R, Kamata K, Inoue K, Kodama T, Ueki K, Kadowaki T. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 13: 294-307, 2011.
25. Li W, Peng H, Cao T, Sato R, McDaniels SJ, Kobori H, Navar LG, Feng Y. Brain-targeted (pro)renin receptor knockdown attenuates angiotensin II-dependent hypertension. Hypertension 59: 1188-1194, 2012.
26. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus A marker of microvascular complications. N Engl J Med 312: 1412-1417, 1985.
27. Matsushima S, Kinugawa S, Yokota T, Inoue N, Ohta Y, Hamaguchi S, Tsutsui H. Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes. Am J Physiol Heart Circ Physiol 297: H409-H416, 2009.
28. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 53: 1062-1069, 2009.
29. Mohammad S, Taha A, Bamezai RN, Baquer NZ. Modulation of glucose transporter (GLUT4) by vanadate and Trigonella in alloxandiabetic rats. Life Sci 78: 820-824, 2006.
30. Moilanen AM, Rysa J, Serpi R, Mustonen E, Szabo Z, Aro J, Napankangas J, Tenhunen O, Sutinen M, Salo T, Ruskoaho H. (Pro)rennin receptor triggers distinct angiotensin ii-independent extracellular matrix remodeling and deterioration of cardiac function. PloS one 7: e41404, 2012.
31. Muller DN, Klanke B, Feldt S, Cordasic N, Hartner A, Schmieder RE, Luft FC, Hilgers KF. (Pro)renin receptor peptide inhibitor “handleregion” peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 51: 676-681, 2008.
32. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294: E15-E26, 2008.
33. Nagai Y, Ichihara A, Nakano D, Kimura S, Pelisch N, Fujisawa Y, Hitomi H, Hosomi N, Kiyomoto H, Kohno M, Ito H, Nishiyama A. Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats. Exp Physiol 94: 1016-1023, 2009.
34. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
35. Nguyen G, Muller DN. The biology of the (pro)renin receptor. J Am Soc Nephrol 21: 18-23, 2010.
36. Ohta Y, Kinugawa S, Matsushima S, Ono T, Sobirin MA, Inoue N, Yokota T, Hirabayashi K, Tsutsui H. Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. Am J Physiol Heart Circ Physiol 300: H1637-H1644, 2011.
37. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38: 1213-1217, 1995.
38. Peng H, Li W, Seth DM, Nair AR, Francis J, Feng Y. (Pro)rennin receptor mediates both angiotensin II-dependent and-independent oxidative stress in neuronal cells. PloS one 8: e58339, 2013.
39. Satofuka S, Ichihara A, Nagai N, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Itoh H, Oike Y, Ishida S. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 48: 422-429, 2007.
40. Shimizu I, Yoshida Y, Katsuno T, Tateno K, Okada S, Moriya J, Yokoyama M, Nojima A, Ito T, Zechner R, Komuro I, Kobayashi Y, Minamino T. p53-Induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab 15: 51-64, 2012.
41. Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp Physiol 93: 709-714, 2008.
42. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 81: 518-527, 1990.
43. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, Ishida Y, Nakamura Y, Murakami K. Human prorenin has “gate and handle” regions for its non-proteolytic activation. J Biol Chem 278: 22217-22222, 2003.
44. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens 9: 277-284, 1996.
45. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 281: 35137-35146, 2006.
46. Wisniacki N, Taylor W, Lye M, Wilding JP. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 91: 32-37, 2005.
47. Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 44: 78-81, 2004.
48. Yokota T, Kinugawa S, Hirabayashi K, Matsushima S, Inoue N, Ohta Y, Hamaguchi S, Sobirin MA, Ono T, Suga T, Kuroda S, Tanaka S, Terasaki F, Okita K, Tsutsui H. Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 297: H1069-H1077, 2009.